Institutional shares held 1.49 Billion
25.9M calls
20M puts
Total value of holdings $65.5B
$1.14B calls
$879M puts
Market Cap $93.6B
2,126,160,000 Shares Out.
Institutional ownership 69.94%
# of Institutions 2,554

Latest Institutional Activity in BMY

Top Purchases

Q1 2024
Charles Schwab Investment Management Inc Shares Held: 53.7M ($2.37B)
Q1 2024
Capital International Investors Shares Held: 70.2M ($3.09B)
Q1 2024
M&G PLC Shares Held: 7.27M ($320M)
Q1 2024
Pzena Investment Management LLC Shares Held: 12.3M ($541M)
Q1 2024
Price T Rowe Associates Inc Shares Held: 12.5M ($552M)

Top Sells

Q1 2024
Vanguard Group Inc Shares Held: 186M ($8.19B)
Q1 2024
Ameriprise Financial Inc Shares Held: 19.8M ($870M)
Q1 2024
Fil LTD Shares Held: 1.21M ($53.4M)
Q1 2024
Black Rock Inc. Shares Held: 163M ($7.16B)
Q1 2024
Deutsche Bank Ag\ Shares Held: 8.18M ($360M)

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Insider Transactions at BMY

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
From 17 Insiders
Exercise of conversion of derivative security 467K shares
Open market or private purchase 13.6K shares
Other acquisition or disposition 9.83K shares
Sell / Disposition
From 28 Insiders
Payment of exercise price or tax liability 160K shares
Other acquisition or disposition 142K shares
Bona fide gift 440 shares
Open market or private sale 18.7K shares

Track Institutional and Insider Activities on BMY

Follow BRISTOL MYERS SQUIBB CO and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BMY shares.

Notify only if

Insider Trading

Get notified when an Bristol Myers Squibb CO insider buys or sells BMY shares.

Notify only if


Receive news related to BRISTOL MYERS SQUIBB CO

Track Activities on BMY